Advances of Cell Therapy in Lung Cancer: a Narrative Review

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2024 Jan 22

PMID 38249856

Authors

Lu Lv

Wenyan Chen

Na Chen

Enhai Cui

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Lung cancer is the second most prevalent malignancy and has the highest death rate. The main approaches for lung cancer treatment include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, the treatments of the disease need to be further improved. An increasing number of scientific investigations indicated cell therapy to be a successful new treatment for lung cancer. Cell therapy can improve the host's immunity to disease and can compensate for the shortcomings in the therapeutic effects of traditional treatments, particularly in the case of cancer treatment. However, due to its recent development, its clinical efficacy still needs to be further examined. In order to provide an updated source on cell therapy for lung cancer, this paper summarizes the clinical use of chimeric antigen receptor T cells (CAR-Ts), stem cells, cytokine-induced killer cells (CIKs), and tumor-infiltrating lymphocytes (TILs) and discusses recent clinical advancements.

Methods: We performed a search of the PubMed database on March 28, 2023, and again on June 10, 2023. A review of retrieved literature related to cell therapy and treatments for lung cancer was completed.

Key Content And Findings: Cell therapy has been applied in clinical studies on the treatment of disorders of the hematologic system, digestive system, respiratory system, and other systems. CAR-T therapy has been successfully used in the treatment of B-cell malignancies, which suggests that cell therapy has broad prospects in the treatment of malignant tumors. CAR-T, stem cells, CIKs, and TILs exert antitumor activity and can recognize and could be used to treat lung cancer.

Conclusions: Cell therapy represents a novel solution in the treatment of lung cancer. Cell therapy, when combined with traditional therapies, can compensate for the shortcomings of these methods. Further research is needed to reduce the occurrence of adverse reactions and provide a more effective approach in treating lung cancer.

References

Chen Q, Cheng P, Yin T, He H, Yang L, Wei Y . Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma. Int J Mol Med. 2012; 30(3):527-34. DOI: 10.3892/ijmm.2012.1015. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C . Current Progress in CAR-T Cell Therapy for Solid Tumors. Int J Biol Sci. 2019; 15(12):2548-2560. PMC: 6854376. DOI: 10.7150/ijbs.34213. View

Sage E, Thakrar R, Janes S . Genetically modified mesenchymal stromal cells in cancer therapy. Cytotherapy. 2016; 18(11):1435-1445. PMC: 5082580. DOI: 10.1016/j.jcyt.2016.09.003. View

Tian L, Yue W, Zhu F, Li S, Li W . Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo. J Cell Physiol. 2011; 226(7):1860-7. DOI: 10.1002/jcp.22511. View

Ye L, Lou Y, Lu L, Fan X . Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors . Exp Ther Med. 2019; 17(1):739-747. PMC: 6307389. DOI: 10.3892/etm.2018.7015. View

Liu S, Meng Y, Liu L, Lv Y, Wei F, Yu W . Rational pemetrexed combined with CIK therapy plus anti-PD-1 mAbs administration sequence will effectively promote the efficacy of CIK therapy in non-small cell lung cancer. Cancer Gene Ther. 2022; 30(2):277-287. DOI: 10.1038/s41417-022-00543-5. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Li Y, Sharma A, Wu X, Weiher H, Skowasch D, Essler M . A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines. Front Oncol. 2022; 12:713476. PMC: 9130779. DOI: 10.3389/fonc.2022.713476. View

10.

Gargett T, Yu W, Dotti G, Yvon E, Christo S, Hayball J . GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016; 24(6):1135-1149. PMC: 4923328. DOI: 10.1038/mt.2016.63. View

11.

Xiao Z, Wang C, Feng J, Zhou M, Wang Y, Li N . Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials. Cytotherapy. 2018; 21(2):125-147. DOI: 10.1016/j.jcyt.2018.10.011. View

12.

Kim E . Chemotherapy Resistance in Lung Cancer. Adv Exp Med Biol. 2015; 893:189-209. DOI: 10.1007/978-3-319-24223-1_10. View

13.

Zhang C, Huang T, Wu B, He W, Liu D . Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017; 8(43):75756-75766. PMC: 5650462. DOI: 10.18632/oncotarget.20798. View

14.

Kosti P, Maher J, Arnold J . Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Front Immunol. 2018; 9:1104. PMC: 5972325. DOI: 10.3389/fimmu.2018.01104. View

15.

Zhong R, Han B, Zhong H . A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumour Biol. 2013; 35(2):987-94. DOI: 10.1007/s13277-013-1132-1. View

16.

Huang J, Kan Q, Lan , Zhao X, Zhang Z, Yang S . Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. Int Immunopharmacol. 2017; 46:170-177. DOI: 10.1016/j.intimp.2016.12.005. View

17.

Zhang Z, Jiang J, Wu X, Zhang M, Luo D, Zhang R . Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy. Front Med. 2019; 13(1):57-68. DOI: 10.1007/s11684-019-0683-y. View

18.

Liu R, Wei S, Chen J, Xu S . Mesenchymal stem cells in lung cancer tumor microenvironment: their biological properties, influence on tumor growth and therapeutic implications. Cancer Lett. 2014; 353(2):145-52. DOI: 10.1016/j.canlet.2014.07.047. View

19.

Hung L, Ngo H, Van Pham P . Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. Adv Exp Med Biol. 2020; 1292:113-130. DOI: 10.1007/5584_2020_522. View

20.

Chen D, Sha H, Hu T, Dong S, Zhang J, Liu S . Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer. Cell Death Dis. 2018; 9(3):366. PMC: 5840363. DOI: 10.1038/s41419-018-0404-5. View